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Introduction
　Cancer-related death in colorectal cancer（CRC）is usually due to the development of dis-
tant metastases.  Approximately 70％ of all patients diagnosed with CRC undergo potentially 
curative surgery, but half of these patients present with, or develop, advanced local disease 
or metastases1）.  Although several prognostic factors exist, including the clinical staging clas-
sication, a more specic recognition marker for CRC with high metastatic potential would 
provide useful information for evaluating adjuvant therapies.  We have already reported a 
correlation between the immunohistochemical expression of CD44 and lymph node and liver 
metastases2）, and more specic markers are required.
　Amino acid transporters are essential for growth and proliferation in normal and trans-
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formed cells 3, 4）.  L-type amino acid transporter 1（LAT1）, one of the L-type amino acid 
transporters, transports large neutral amino acids such as leucine, isoleucine, valine, phenylala-
nine, tyrosine, tryptophan, methinine and histidine5-7）.
　LAT1 expression is closely related to liver metastases in a rat tumor model 8）, but little 
is known about this relationship in human primary digestive organ tumors9）.  The aim of 
the present study was to examine LAT1 expression in CRC with invasion to the subserosal 
layer（T3）, and its relationship with potential liver metastases and associated clinicopatho-
logical characteristics.  Because liver metastasis occurs more frequently in T3 than in T1
（invasion to the submucosal layer）or T2（invasion to the muscular layer）tumors, it is 
important to clarify whether LAT1 expression in cancer cells would be a good marker for 
predicting potential liver metastasis in T3 CRC.
Fig. 1.　Low power view of colorectal cancer（CRC）.
Typical CRC with invasion to the subserosal layer（T3）is shown. 
Hematoxylin and eosin staining ; magnication ×1.25.
Fig. 2.　Immunohistochemical staining for L-type amino acid transporter 1（LAT1）.
（A） More than 10％ of the tumor cell membranes are stained and the tumor is graded as posi-
tive. Magnication ×400.
（B）Tumor cells are not stained and the tumor is graded as negative. Magnication ×400.
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Materials and Methods
　Tissue samples from 65 patients who had primary T3 CRC surgically resected at the 
Showa University Hospital between 2004 and 2007 were enrolled in this retrospective 
study.  The non-necrotic portion of the tumor was processed using the standard parafn wax 
technique after xation in 10％ formalin for 24 hours.  Representative sections were stained 
with hematoxylin and eosin.  T1, T2, and T4（invasion to the serosa）tumors were not 
examined, because sufcient cases could not be collected for meaningful statistical analysis.
Immunohistochemistry
　From representative blocks of each tissue sample, 3-μm thick sections were used for 
immunohistochemical staining with the monoclonal antibody clone 4D9（anti-LAT1 ; Trans-
genic, Hyogo, Japan）, at a dilution of 1 : 200.  The streptavidin-biotin-peroxidase technique 
was used.  Sections were deparaffinized in xylene and dehydrated in descending grades
（100％-50％）of ethanol, and then subjected to antigen retrieval（microwave method using 
citrate buffer［pH 6.0］, 25 minutes）.  After the slides had cooled to room temperature, 
they were incubated with 1％ hydrogen peroxide in ethanol for 30 minutes to quench 
endogenous peroxidase activity.  Nonspecic immunoreactivity was blocked in each section 
by incubation with normal donkey serum for 30 minutes.  The sections were then incubated 
with primary antibody at 4° C overnight.  After three, 5-minute washes with phosphate-buff-
ered saline（PBS）, the sections were incubated for 60 minutes with a multilink biotinylated 
anti-immunoglobulin（Dako, Kyoto, Japan）.  Sections were then washed with PBS three 
times for 5 minutes, before and after being treated with streptavidin-peroxidase reagent for 
30 minutes.  The reactions were visualized with diaminobenzidine（Dako）as the chromogen. 
All steps were followed by adequate washes in PBS.  Finally, sections were counterstained 
with hematoxylin, dehydrated and mounted.  LAT1 expression was considered positive only 
if distinct membranous immunoreactivity was present.  The tumors in which immunoreactive 
tumor cells made up ＞10％ of the tumor were graded as positive.  This 10％ cut-off value 
is widely used by many authors9, 10）.  All histological slides were examined by two experi-
enced pathologists unaware of the clinical data or disease outcome.
Statistical analysis
　The association of LAT1 expression with clinicopathological features, such as age, gender, 
tumor location, tumor size, macroscopic / microscopic classication, lymph node metastasis and 
liver metastasis1）, was examined using the χ2 test as appropriate.  P＜0.05 was considered 
statistically signicant.
Results
　The characteristics of the study population are shown in Table 1.  The subjects consisted 
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of 47 men（72.3％）and 18 women（27.7％）, with a mean age of 68.71 years（range, 29—90 
years）and a mean tumor size of 4.5 cm（range, 1.2—9.5 cm）.
　LAT1 expression in the primary tumor was demonstrated in 29.3％（19 of 65）of patients. 
The relationships between tumor LAT1 expression and the clinicopathological parameters 
of CRC are also summarized in Table 1.  LAT1 expression in the primary tumor was not 
signicantly associated with age, gender, tumor location, tumor size, macroscopic classication, 
microscopic classication, or lymph node metastases.  However there was a positive associa-
tion between LAT1 expression and liver metastases, with 22.4％ of M0 cases and 50.0％ of 
M1 cases showing positive LAT1 expression in the primary tumor（P＜0.05 ; Table 1）.
Discussion
　LAT1 expression is associated with cancerous or proliferative cells, and LAT1 is sug-
gested to be involved in the mechanism allowing continuous proliferation of tumor cells 6, 7）. 
Table 1　LAT1 expression and clinicopathological parameters of CRC（n＝65）
LAT1 expression, n（％）
n - ＋ P
Age（years）
＜60 12 10（83.3）  2（16.7） NS
60 53 36（67.9） 17（32.1）
Gender
Male 47 35（74.5） 12（25.5） NS
Female 18 11（61.1）  7（38.9）
Tumor location
Colon 51 37（72.5） 14（27.5） NS
Rectum 14  9（64.3）  5（35.7）
Tumor size（cm）
＜5.0 36 26（72.2） 10（27.8） NS
5.0 29 20（68.9）  9（31.1）
Macroscopic classication
Type2 54 36（66.7） 18（33.3） NS
Type3 11 10（90.9）  1　（9.1）
Microscopic classication
Tub1 20 12（60.0）  8（40.0） NS
Tub2 / por 45 34（75.6） 11（24.4）
Lymph node metastasis（N）
N0 30 19（63.3） 11（36.7） NS
N1 / 2 35 27（77.1）  8（22.9）
Liver metastasis（M）
M0 49 38（77.6） 11（22.4） P＜0.05
M1 16  8（50.0）  8（50.0）
LAT1, L-type amino acid transporter 1 ; CRC, colorectal carcinoma ; NS, not 
signicant
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Immunohistochemical studies have found LAT1 to be highly expressed in cultured cells and 
malignant tumors, such as oral squamous cell carcinomas11）, esophageal squamous cell car-
cinomas12）, gliomas13）, urothelial carcinoma of the upper urinary tract14）, and non-small cell 
lung cancers15, 16）.  The clinical signicance of LAT1 expression has been fully investigated 
by Imai et al10） and Kaira et al 15） in pulmonary cancers.  They found a high lymphatic 
permeation and vascular invasion and a low ve-year survival rate in LAT1-positive cases, 
and concluded that LAT1 expression is a signicant factor in predicting a poor prognosis. 
Sakata and colleagues17） also found a poor prognosis in LAT1-positive prostate cancer cases, 
and concluded that LAT1 was a novel biomarker for high-grade malignancy.  However little 
is known about the clinical significance of LAT1 expression in digestive system cancers, 
especially CRC 9）.
　In rat colonic cancer models, LAT1 expression has been described as being associated 
with metastasis in vivo 8, 18）.  When rat colon cancer cells（RCN-9）were injected into the 
spleen of rats, the size of the resultant metastatic liver tumors was directly correlated with 
LAT1 expression8, 18）.  These studies support our nding that LAT1 expression showed a sig-
nicantly positive relationship with liver metastasis in patients with T3 CRC.  There is only 
one previous report concerning LAT1 expression in human CRC.  Kaira et al 9） examined 
LAT1, CD98 and Ki-67 expression in pulmonary metastases from colon cancer and other 
cancers, and reported that cancer cells in the metastatic foci showed higher LAT1 expres-
sion, indicating higher angiogenesis and cell proliferation, than those in the primary foci. 
In contrast to the report of Kaira et al9）, the present study showed a difference in LAT1 
expression between cases with and without metastases, and revealed the clinical signicance 
of LAT1 expression in CRC.  However apart from liver metastasis, our results showed no 
relationship with any other clinical factor, such as lymph node metastasis.  Although the 
reason is unknown, further studies are necessary to clarify the relationship between LAT1 
expression and lymph node metastasis, because of its prognostic signicance.
　From a therapeutic point of view, reports about inhibitors of LAT1, such as L-leucine, 
2-aminobicyclo-2（2,2,1）-heptane-2-carboxylic acid（BCH）, melphalan and D-leucine, are 
increasing.  L-leucine is reported to inhibit the growth of KB human oral cancer cells 19）, 
while other studies conducted using a rat glioma model 20） and human neck cancer cell 
line 21） describe BCH as a specic inhibitor of LAT1, which inhibits the uptake of the essen-
tial amino acid, leucine.  Furthermore, Shennan and Thomson 22） have described melphalan 
and D-leucine as inhibiting the growth of cultured breast cancer cells.
　Thus, inhibitors of LAT1 may inhibit cancer cell growth, therefore a personalized selective 
therapy using specic inhibitors of LAT1 might have therapeutic potential for cancer patients 
with LAT1 expression20-24）.
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